PHARMAC Pharmaceutical Management Agency

Level 9, 40 Mercer Street, Wellington 6011 PO Box 10-254, Wellington 6143, New Zealand

> Phone 64-4-460-4990 Fax 64-4-460-4995 Information line 0800 66 00 50 enquiry@pharmac.govt.nz www.pharmac.govt.nz

11 November 2016

Dear Service Provider

REQUEST FOR PROPOSALS – SUPPLY OF DISTRIBUTION AND ASSOCIATED LOGISTICAL SERVICES IN RESPECT OF FUNDED NICOTINE REPLACEMENT THERAPY AND CONDOMS TO COMMUNITY HEALTH ORGANISATIONS

PHARMAC invites proposals for the supply of distribution and associated logistical services in respect of funded nicotine replacement therapy and condom pharmaceuticals to community health organisations in New Zealand.

This request for proposals (**RFP**) letter incorporates the following schedules:

- **Schedule 1** specifies the services for which PHARMAC is requesting proposals and sets out the background to the RFP;
- **Schedule 2** describes the process that PHARMAC expects to follow in relation to the RFP;
- **Schedule 3** specifies the information you need to include with your proposal; and
- Two appendices include further information in relation to:
 - **Appendix 1** Service specifications and indicative agreement structure.
 - **Appendix 2** Pack size data and pharmaceutical order summaries.

If you wish to submit a proposal, please submit it to PHARMAC via the Government Electronic Tenders Service (GETS) (<u>www.gets.govt.nz</u>) no later than **4.00 p.m**. on **Friday 9 December 2016**.

If you have any inquiries about this RFP you should submit them via GETS or alternatively contact Matthew Wolfenden, Procurement Manager, by email <u>procurement@pharmac.govt.nz</u>.

We look forward to receiving your proposal.

Yours sincerely

Sarah Fitt

Sarah Fitt Director of Operations

Schedule 1: Description of services and background to RFP

1. Description of services

PHARMAC is interested in considering any proposal from suppliers to provide distribution and associated logistical services ("**Services**") for funded nicotine replacement therapy (NRT) products and condom pharmaceuticals ("**Pharmaceuticals**") to be distributed in bulk to community health organisations in New Zealand.

The Services would contribute to PHARMAC's goal of widening the options for providing funded pharmaceuticals to patients, removing barriers to access and ensuring that the pharmaceutical funding system remains fit-for-purpose and sustainable.

A summary of the Services we are seeking proposals for is provided below:

- Pharmaceutical distribution and logistical services
- Reporting

Please refer to Appendix 1 for the full service specifications and for the indicative agreement structure which PHARMAC would expect to enter into with a service provider. The indicative agreement structure has been provided in order to assist you in the planning of your proposal. PHARMAC reserves the right to amend any part of the indicative agreement structure and any resulting agreement before and during negotiations.

Further information about funded NRT and condoms can be found in Appendix 2.

Pre-requisites for provider

 Ability to provide the Services in accordance with the <u>New Zealand Code of Good</u> <u>Manufacturing and Warehousing Practice for Manufacture and Distribution of</u> <u>Therapeutic Goods</u>.

2. Types of proposal sought

PHARMAC is willing to consider proposals for the provision of Services described in this RFP for a period of approximately three years commencing from as early as 1 July 2017 until 30 June 2020, with the option to extend the agreement for up to an additional two years with the same or modified service requirements, until 30 June 2022.

For the avoidance of doubt, PHARMAC will be running a separate competitive process for the supply of funded Nicotine Replacement Therapy (NRT) products, which could result in some changes to the funded treatments from 1 July 2017 at the earliest.

In addition, the Services may require amendment during the term of the agreement, for example but not limited to an adjustment to the volume of the pharmaceuticals distributed and the distribution points to which the pharmaceuticals are delivered.

3. Background to RFP

The current funding and distribution arrangements for NRT and condoms are outlined below:

Nicotine Replacement Therapy

NRT means any formulation of nicotine, including (but not limited to) gum, patches, lozenges, nasal spray and inhaler, that is used as an aid to smoking cessation.

In addition to listing of NRT products on the Pharmaceutical Schedule and the dispensing of these products via community pharmacies, certain NRT products are also provided, fully funded by PHARMAC, directly to third party organisations in New Zealand (collectively referred to as "NRT Authorised Providers"). These include prison services, health service providers contracted by the Ministry of Health to provide smoking cessation services and public health units. The cost of the direct distribution of NRT to these providers is currently included within the subsidised price of the funded NRT products. The successful outcome of this RFP will de-couple the cost of distribution direct to third party organisations (other than community pharmacies) from the subsidised price of funded NRT products.

Orders from NRT Authorised Providers are managed via PHARMAC Online (<u>www.pharmaconline.co.nz</u>) and distribution of funded NRT is currently arranged by the NRT supplier. Orders are distributed quarterly and can be placed at any time during the quarter up until the order deadline for each quarter. Delivery of the entire order is expected to occur within 4 weeks of the quarterly order deadline. The supplier invoices PHARMAC directly for the pharmaceutical cost.

Following a change to the Ministry of Health contracted service providers on 1 July 2016, there are now approximately 48 NRT Authorised Providers in total. Details of the last two quarterly orders are shown in Appendix 2.

Condoms

PHARMAC has agreements with the New Zealand Aids Foundation (NZAF) and the New Zealand Prostitutes Collective Charitable Trust (NZPC) to provide funding for the bulk purchase of condoms for distribution within the community. The agreements provide for delivery of a combined total of 10,500 packs of the equivalent of the 144 pack size of condoms over any 12 month period.

There are nine delivery locations: Auckland (2), Christchurch (2), Wellington (2), Palmerston North, Tauranga and Dunedin. We anticipate that monthly deliveries will be required to each site.

4. Desired Outcome

- PHARMAC would:
 - $\circ\,$ manage orders from NRT Authorised Providers, NZAF and NZPC via PHARMAC Online; and
 - summarise monthly orders for condoms and quarterly orders for NRT and send them electronically as a purchase order to the successful service provider.
- The service provider would:
 - purchase stock from PHARMAC's nominated suppliers for funded pharmaceuticals in accordance with orders received from PHARMAC;
 - then arrange the distribution and logistics to ensure that all orders are delivered in full, within a set period to be agreed;
 - o provide PHARMAC with agreed reports; and
 - o invoice PHARMAC electronically for the orders delivered in full.
- For the avoidance of doubt, no re-packing of the pharmaceuticals will be required by the service provider. All orders will be for whole packs.

Schedule 2: RFP Process

PHARMAC expects to follow the process set out below in the sequence indicated.

1. Submission

- (a) You may submit more than one proposal. Each proposal will be considered as a separate proposal.
- (b) Proposals must be submitted to PHARMAC via the Government Electronic Tenders Service (GETS) no later than 4.00 p.m. (New Zealand time) on Friday 9 December 2016. Late proposals will only be considered at PHARMAC's discretion, taking into account the need for fairness to other service providers and integrity of the RFP process.
- (c) You cannot withdraw your proposal, once submitted, while the RFP process is continuing.
- (d) If you have any inquiries about this RFP you should submit them via GETS or alternatively contact Matthew Wolfenden, Procurement Manager, by email procurement@pharmac.govt.nz.

2. Evaluation

- (a) Following the deadline for submitting proposals an Evaluation Committee comprising PHARMAC staff will evaluate each proposal to select its preferred proposal(s).
- The Evaluation Committee will evaluate proposals in light of PHARMAC's statutory (b) objective which is "to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided". In doing so the Evaluation Committee will be guided by the Factors for Consideration (Factors) that form part of PHARMAC's then current Operating Policies and Procedures (OPPs), as published on PHARMAC's website (www.pharmac.govt.nz), to the extent applicable. More information on the Factors can be found at www.pharmac.health.nz/factors-for-consideration.
- (c) The information to be taken into account in applying the Factors by the Evaluation Committee will be at its discretion, however it will include (in order of priority):
 - (i) Description of method of the Services;
 - (ii) your organisation's activities/experience/credentials in delivering services of the type required;
 - (iii) price information;
 - (iv) the information included in your proposal in the form set out in Schedule 3 of this RFP; and
 - (v) any other information that the Evaluation Committee considers to be relevant having regard to probity principles.
- (d) Each proposal will be evaluated on the basis that the price offered, the expenditure entailed, and any other terms included in the proposal, are the best that the service provider is able to offer. If you do not put forward your best terms you risk having your proposal excluded at the evaluation stage.

(e) PHARMAC is not bound to select the lowest priced proposal or any proposal.

3. **PHARMAC may request further information**

- (a) PHARMAC may request such further information as it considers necessary from or about you for the purposes of clarifying or evaluating your proposal.
- (b) If PHARMAC requests further information from or about you, it is not obliged to request the same or any other information from or about any other party, provided that in PHARMAC's judgment this would not be unfair to any other party.

4. Negotiation

- (a) PHARMAC may negotiate with the submitter(s) of one or more preferred proposals, in the latter case whether or not the acceptance of either service provider's proposal would exclude acceptance of the other proposal.
- (b) Negotiations will proceed on the basis that the agreement structure set out in Appendix 1 will apply, which will be developed into a full provisional agreement.
- (c) Given that PHARMAC expects your proposal to be the best you can offer, PHARMAC does not intend to initiate negotiation with you on price. However, PHARMAC does not exclude the possibility that the final price agreed will be different from the price put forward in your proposal, as a result of the impact that other negotiated terms may have on price.
- (d) PHARMAC may negotiate and enter into a provisional agreement with a preferred service provider(s) on whatever special terms PHARMAC considers appropriate.
- (e) If PHARMAC and the service provider(s) are unable to reach a provisional agreement within what PHARMAC considers to be a reasonable time, PHARMAC may terminate those negotiations and negotiate with a different service provider(s).

5. **Consultation and approval**

- (a) Any provisional agreement will be conditional on consultation (at PHARMACS's discretion) with other interested parties, to the extent PHARMAC considers consultation to be necessary or appropriate, and on Board approval (or approval by the Board's delegate acting under delegated authority).
- (b) PHARMAC will not consider any counter-offers received during consultation.
- (c) The provisional agreement and responses to consultation will be considered (if applicable) by PHARMAC's Board (or by the Board's delegate acting under delegated authority) in accordance with the Factors in PHARMAC's then current OPPs.
- (d) If the Board or its delegate does not approve the provisional agreement, then PHARMAC may initiate negotiations for a provisional agreement with any other service provider(s).
- (e) The RFP process will be complete once PHARMAC has notified service providers of either:
 - (i) the Board's or its delegate's decision to accept a negotiated agreement; or
 - (ii) the termination of the RFP process.

6. Miscellaneous

- (a) PHARMAC reserves the right, having regard to probity principles:
 - to make such adjustments to the above RFP process as it considers appropriate, at any time during the process, provided that it notifies service providers affected by those changes;
 - (ii) to meet with any submitter of a proposal at their place of business to discuss their proposal and to gain an understanding of their work environment;
 - (iii) not to accept any proposal;
 - (iv) to seek clarification of any proposal;
 - (v) to meet with any service provider in relation to its proposal;
 - (vi) to enter into an agreement or arrangement that differs in material respects from that envisaged in this RFP letter;
 - (vii) to suspend this RFP process. For example, if during the RFP process (and before a provisional agreement is entered into) it becomes apparent to PHARMAC that further consultation is appropriate or required we may suspend the RFP process in order to consult. In this situation we may ask you to adapt and resubmit your proposal in light of consultation, or alternatively we may request that new proposals be submitted;
 - (viii) to terminate this RFP process at any time, by notifying service providers who submitted proposals, and, following termination, to negotiate with any service providers(s) on whatever terms PHARMAC thinks fit; and
 - (ix) to re-advertise for proposals.
- (b) You must not initiate or engage in any communication with other service providers in relation to the RFP, whether before or after submitting their proposal(s), until such time as a provisional agreement is accepted by PHARMAC's Board or the Board's delegate.
- (c) You must not at any time initiate any communication with PHARMAC, the Ministry of Health (including its operating unit Medsafe), the Minister of Health (or any Associate Ministers) or DHBs or advisors to PHARMAC with a view to influencing the outcome of this RFP process.
- (d) You must pay your own costs for preparing and submitting your proposal.
- (e) Proposals are submitted in reliance on your own knowledge, skill, and independent advice, and not in reliance on any representations made by PHARMAC.
- (f) Your submission of a proposal will be taken as acceptance of the terms contained in this RFP letter. PHARMAC may exclude your proposal if you do not comply with any of the terms contained in this RFP letter.
- (g) This is an RFP and not a tender. Your proposal is not an offer capable of being converted into a contract for the supply of distribution and associated logistical services of pharmaceuticals to community health organisations in New Zealand by PHARMAC's apparent acceptance and instead a separate agreement needs to be negotiated.

- (h) PHARMAC is not liable in any way whatsoever for any direct or indirect loss (including loss of profit), damage or cost of any kind incurred by you or any other person in relation to this RFP.
- PHARMAC will consider your proposal and information exchanged between us in any negotiations relating to your proposal, excluding information already in the public domain, to be confidential to us and our employees, legal advisors and other consultants, the Ministry of Health and DHBs (**Confidential Information**). However, you acknowledge that it may be necessary or appropriate for PHARMAC to release Confidential Information:
 - (i) pursuant to the Official Information Act 1982; or
 - (ii) in the course of consultation on a provisional agreement entered into with a service provider; or
 - (iii) in publicly notifying any approval by the PHARMAC Board of that agreement; or
 - (iv) otherwise pursuant to PHARMAC's public law or any other legal obligations.

PHARMAC may consult with you before deciding whether to disclose Confidential Information for the purposes described in sub-clauses (i) to (iv) above. You acknowledge, however, that it is for PHARMAC to decide, in its absolute discretion, whether it is necessary or appropriate to disclose information for any of the above purposes, provided that PHARMAC shall act in good faith in disclosing any Confidential Information.

(j) PHARMAC is bound by obligations under law and the terms of this RFP are subject to those obligations.

7. Anticipated timetable

- (a) Following receipt of proposals, PHARMAC anticipates:
 - (i) the Evaluation Committee evaluating proposals in **December 2016**;
 - (ii) negotiating with submitter(s) of one or more preferred proposals in **January 2017**;
 - (iii) if applicable consulting on a provisional agreement by February 2017;
 - (iv) PHARMAC's Board or its delegate considering the provisional agreement in or after **February 2017**,

provided that the above time frames are only approximate and may be extended, without notice being required from PHARMAC, if any stages of the RFP process take longer than anticipated.

8. Governing Law

This RFP is governed by New Zealand law, and the New Zealand courts have exclusive jurisdiction in all matters relating to this RFP.

Schedule 3: Information to be included in the proposal

1. Organisation Details

Identify and describe your organisation as follows:

- Legal name of your organisation (and including any trading name).
- Name and position of your contact person and their contact details.
- Your organisation's activities/experience/credentials in delivering services of the type required.
- The dimensions of the organisation (e.g. size, location, turnover, management, staff, financial size/status/stability).
- The hours of operation for your organisation.
- Names and contact points for two or more referees PHARMAC may approach.

2. Details of Proposal(s)

- Description of Method of the Services Describe how you intend to approach and provide the Services outlined in Schedule 1 and Appendix 1, using the current distribution volumes in Appendix 2, including:
 - An outline of the phases and timeframes for establishing the services, including a transition plan (if applicable);
 - The proposed arrangements and procedures/process for delivering the Services;
 - How orders would be processed.
 - Your transportation method.
 - Your ability to track orders.
 - How receipt of goods is verified on delivery.
 - Reporting capabilities.
 - How the Services would be positioned and supported within your organisational structure; and
 - Proposals/suggestions about Services not expressly identified in the RFP that PHARMAC may wish to consider.
- Resources and personnel Identify the resources and personnel that will be applied/engaged to deliver the Services. Identify and include details about the person who will assume overall responsibility for delivery of the Services (Key Account Manager).

3. Financial

- Price for delivering the Services:
 - please specify your delivery price structure;
 - o including occasional "out of cycle" additional orders; and
 - $\circ~$ estimate the total cost per year based on the information provided.
- All prices must be GST excusive.

4. Other items that need to be included

- a. **Settings**: you should describe the various licences and consents held, your facilities / buildings, plant and equipment, hours of operation and subcontracting relationships.
- b. Operational standards. You should describe:
 - Your quality (including any self and external audit) and risk management processes and systems.
- c. Linkages. You should describe:
 - Account relationship management processes.
 - Pharmaceutical provider relationship management processes.

5. General Requirements

Ensure that your proposal addresses each of the following general requirements:

- a. **Professional expertise**: You and your staff must have the appropriate skills and expertise to ensure the safe and secure distribution and associated logistical services of pharmaceuticals to community health organisations in New Zealand.
- b. Quality: You should demonstrate how you will ensure that the Services required will be of excellent quality. For example, you will need to demonstrate previous experience in the distribution and associated logistical services of pharmaceuticals and describe the quality features of that previous experience. You should describe the quality assurance processes that will apply to your provision of Services.
- c. **Service Priorities**: You must show that you are able to put aside adequate time and dedicate appropriate resources for the Services to be provided under the agreement to ensure that the provision of the Services is not compromised by your other commitments. This will include ensuring the Services are appropriately positioned within the organisation and have access to appropriate levels of support and facilities to ensure their effective operation.
- d. Joint Ventures or Sub-Contracting: If you intend entering into a joint venture or employing sub-contractors in order to provide the Services, those other parties to the venture or the sub-contractors must meet the requirements of this RFP. You should specify how you would ensure that they would meet these requirements, and each such party should be identified clearly in your proposal.
- e. **Conflict of Interest**: No conflict of interest shall occur. Identify any likely conflicts and how you would resolve them.

APPENDIX 1

Reference to 'funded pharmaceuticals' in this section includes all Nicotine Replacement Therapy (NRT) and condom pharmaceuticals listed in Section B and Section H of the Pharmaceutical Schedule subject to any variation to the funded pharmaceuticals during the term of any agreement.

Service Specification

1. Pharmaceutical Distribution and Logistical Services

You will:

- a) have the capability of receiving orders from PHARMAC electronically;
- b) place orders and purchase stock from PHARMAC's nominated suppliers for funded pharmaceuticals based on demand;
- c) store any funded pharmaceutical stock in accordance with the New Zealand Code of Good Manufacturing and Warehousing Practice for Manufacture and Distribution of Therapeutic Goods;
- d) ensure that your infrastructure has capacity for stock of funded pharmaceuticals and additional capacity for pharmaceuticals that may be approved for funding in the future.
- e) dispatch funded pharmaceuticals to NRT Authorised Providers, NZAF and NZPC (as appropriate) and to any other party that PHARMAC requests, within a maximum of 10 working days of receiving an order;
- f) obtain a signature or courier ticket statement on receipt by an approved community health organisation, of every funded pharmaceutical delivery.

2. Reporting

You will provide monthly reports to PHARMAC on a specified day each month which include:

 a) stock summary (distribution data by NRT Authorised Providers, NZAF and NZPC, number of deliveries per month by each NRT Authorised Provider, NZAF and NZPC).

Indicative Agreement Structure

General Terms

- 1. Definitions.
- 2. Operating Policies and Procedures.
- 3. Term.
- 4. Pharmaceutical Services.
- 5. Pharmaceutical Recall, Transition Services (if applicable) and Disengagement Services.
- 6. Emergency and Disaster Supply Arrangements
- 7. Invoicing and Payments.
- 8. Information and Reporting.
- 9. Audit.
- 10. Notification.
- 11. Insurance.
- 12. Risk.
- 13. Liability and Indemnity.
- 14. Default interest and Recovery Costs.
- 15. Termination.
- 16. Confidentiality.
- 17. Conflict of Interest.
- 18. Litigation Support.
- 19. Dispute Resolution.
- 20. Force Majeure.
- 21. Notices.
- 22. Amendments to Pharmaceutical Schedule.
- 23. Consents.
- 24. No Derogation.
- 25. No Waiver.
- 26. Agreement Prevails.
- 27. Entire Agreement.
- 28. Contracts Privity.
- 29. No Reliance.
- 30. Amendments.
- 31. Assignment.
- 32. Further Assurances.
- 33. Governing Law and Jurisdiction.

Schedule 1 - Special Obligations

Schedule 2 – Service Specification

APPENDIX 2

1. Pack dimension and price information

- a. The following table gives an indication of the packaging dimensions and prices for pharmaceuticals currently funded. The brands, and therefore dimensions, and number of pharmaceuticals are subject to change as and when PHARMAC make amendments to the Pharmaceutical Schedule.
- b. It should be noted that packaging configuration determines the minimum order quantity for each pharmaceutical type, i.e. one pack.
- c. Prices per pack are ex. manufacturer excluding GST.

Pharmaceutical Type	Description	Pharmacode	Brand	Price per pack	No of units per pack	Weight (kg)	L (mm)	W (mm)	H (mm)
	Patch 7 mg	2381389	Habitrol	\$10.57	28	0.064	35	100	110
	Patch 14 mg	2381397	Habitrol	\$11.31	28	0.099	35	90	100
	Patch 21 mg	2381400	Habitrol	\$11.95	28	0.129	35	100	110
NDT	Lozenge 1 mg	2381370	Habitrol	\$12.91	216	0.320	120	120	55
NRT	Lozenge 2 mg	2381362	Habitrol	\$14.14	216	0.325	115	115	55
	Gum 2 mg (Fruit)	2381354	Habitrol	\$22.26	384	0.600	114	107	112
	Gum 2 mg (Mint)	2381346	Habitrol	\$22.26	384	0.600	114	107	112
	Gum 4 mg (Fruit)	2381338	Habitrol	\$25.67	384	0.600	114	107	112
	Gum 4 mg (Mint)	2381311	Habitrol	\$25.67	384	0.600	114	107	112
	49 mm	2099462	Shield 49	\$13.36	144	0.55	170	130	115
	53 mm	2144344	Shield Blue	\$1.11	12	0.05	120	80	50
	53 mm	2144352	Shield Blue	\$13.36	144	0.55	170	130	115
	60 mm	2256878	Shield XL	\$13.36	144	0.56	170	130	115
	53 mm	731161	Gold Knight	\$1.11	12	0.05	120	80	50
	53 mm chocolate	423351	Gold Knight	\$1.11	12	0.05	120	80	50
Condoms	53 mm chocolate	2287757	Gold Knight	\$13.36	144	0.55	170	130	115
	53 mm Strawberry	327050	Gold Knight	\$1.11	12	0.05	120	80	50
	53 mm Strawberry	2287749	Gold Knight	\$13.36	144	0.55	170	130	115
	56 mm	2287781	Gold Knight	\$1.11	12	0.05	120	80	50
	56 mm	2287803	Gold Knight	\$13.36	144	0.55	170	130	115
	56 mm Shaped	301353	Durex Confidence	\$1.11	12	0.05	63	37	124
	56 mm Shaped	493171	Durex Confidence	\$13.36	144	0.58	228	135	128
	56 mm	2309440	Durex Extra Safe	\$13.36	144	0.69	248	123	101

2. NRT orders for July and October 2016

Location	Order Number	Description	Number of Packs
Auckland	1	NRT: Nicotine Lozenges 1mg	3
		NRT: Nicotine Lozenges 2mg	2
	2	NRT: Nicotine Lozenges 1mg	216
		NRT: Nicotine Lozenges 2mg	432
	3	NRT: Nicotine Patches 14mg	216
	4	NRT: Nicotine Lozenges 1mg	432
		NRT: Nicotine Lozenges 2mg	540
		NRT: Nicotine Patches 14mg	360
		NRT: Nicotine Patches 7mg	40
		NRT: Nicotine Patches 21mg	480
		NRT: Nicotine Gum 2mg (Fruit)	160
		NRT: Nicotine Gum 2mg (Mint)	160
		NRT: Nicotine Gum 4mg (Fruit)	128
		NRT: Nicotine Gum 4mg (Mint)	128
Blenheim	5	NRT: Nicotine Gum 2mg (Fruit)	31
		NRT: Nicotine Gum 2mg (Mint)	21
		NRT: Nicotine Gum 4mg (Fruit)	16
		NRT: Nicotine Gum 4mg (Mint)	16
		NRT: Nicotine Lozenges 1mg	30
		NRT: Nicotine Lozenges 2mg	50
		NRT: Nicotine Patches 21mg	70
		NRT: Nicotine Patches 14mg	20
Christchurch	6	NRT: Nicotine Lozenges 2mg	216
		NRT: Nicotine Patches 21mg	120
	7	NRT: Nicotine Lozenges 1mg	40
		NRT: Nicotine Lozenges 2mg	50
		NRT: Nicotine Patches 21mg	10
	8	NRT: Nicotine Gum 2mg (Fruit)	80
		NRT: Nicotine Gum 2mg (Mint)	94
		NRT: Nicotine Gum 4mg (Fruit)	81
		NRT: Nicotine Gum 4mg (Mint)	76
		NRT: Nicotine Lozenges 1mg	212
		NRT: Nicotine Lozenges 2mg	462
		NRT: Nicotine Patches 21mg	520
		NRT: Nicotine Patches 14mg	310
		NRT: Nicotine Patches 7mg	190
Dunedin	9	NRT: Nicotine Gum 2mg (Fruit)	32
	-	NRT: Nicotine Gum 2mg (Mint)	16
		NRT: Nicotine Gum 4mg (Fruit)	48
		NRT: Nicotine Gum 4mg (Mint)	48
		NRT: Nicotine Lozenges 2mg	432
		NRT: Nicotine Patches 21mg	360
		NRT: Nicotine Patches 14mg	120
		NRT: Nicotine Patches 7mg	120
Hamilton	10		
		NRT: Nicotine Gum 2mg (Fruit)	80
		NRT: Nicotine Gum 2mg (Mint)	48
		NRT: Nicotine Gum 4mg (Fruit)	48

Table 1. Summary of July 2016 NRT Orders – 28 sites

		NRT: Nicotine Gum 4mg (Mint)	320
		NRT: Nicotine Lozenges 1mg	324
		NRT: Nicotine Lozenges 2mg	1188
		NRT: Nicotine Patches 21mg	1260
		NRT: Nicotine Patches 14mg	300
		NRT: Nicotine Patches 7mg	120
Hastings	11	NRT: Nicotine Gum 4mg (Fruit)	20
laotingo		NRT: Nicotine Gum 4mg (Mint)	20
		NRT: Nicotine Patches 21mg	60
		NRT: Nicotine Patches 14mg	30
	12	NRT: Nicotine Lozenges 1mg	324
		NRT: Nicotine Lozenges 2mg	432
		NRT: Nicotine Patches 21mg	120
Invercargill	13	· · · · · · · · · · · · · · · · · · ·	54
mvercargin	15	NRT: Nicotine Lozenges 1mg NRT: Nicotine Lozenges 2mg	108
		• •	120
		NRT: Nicotine Patches 21mg	
	14	NRT: Nicotine Patches 14mg	120
	14	NRT: Nicotine Gum 2mg (Fruit)	224
		NRT: Nicotine Gum 2mg (Mint)	192
		NRT: Nicotine Gum 4mg (Fruit)	192
		NRT: Nicotine Gum 4mg (Mint)	192
		NRT: Nicotine Lozenges 1mg	432
		NRT: Nicotine Lozenges 2mg	648
		NRT: Nicotine Patches 21mg	1200
		NRT: Nicotine Patches 14mg	720
		NRT: Nicotine Patches 7mg	120
	15	NRT: Nicotine Gum 4mg (Fruit)	30
		NRT: Nicotine Gum 4mg (Mint)	30
		NRT: Nicotine Patches 21mg	30
		NRT: Nicotine Patches 14mg	30
Kaikohe	16	NRT: Nicotine Lozenges 2mg	162
		NRT: Nicotine Patches 21mg	180
		NRT: Nicotine Patches 14mg	180
		NRT: Nicotine Patches 7mg	180
Lower Hutt	17	NRT: Nicotine Lozenges 2mg	10
		NRT: Nicotine Gum 4mg (Fruit)	10
		NRT: Nicotine Patches 14mg	10
		NRT: Nicotine Gum 4mg (Fruit)	4
		NRT: Nicotine Lozenges 2mg	6
		NRT: Nicotine Patches 21mg	10
		NRT: Nicotine Patches 21mg	8
Palmerston North	18	NRT: Nicotine Lozenges 1mg	216
		NRT: Nicotine Lozenges 2mg	216
	19	NRT: Nicotine Gum 2mg (Fruit)	10
		NRT: Nicotine Gum 2mg (Mint)	10
		NRT: Nicotine Gum 4mg (Fruit)	170
		NRT: Nicotine Gum 4mg (Mint)	10
		NRT: Nicotine Lozenges 1mg	10
		NRT: Nicotine Lozenges 2mg	180
		NRT: Nicotine Patches 21mg	190
		NRT: Nicotine Patches 14mg	40
		NRT: Nicotine Patches 7mg	30

Rotorua	20	NRT: Nicotine Gum 2mg (Fruit)	192
		NRT: Nicotine Gum 2mg (Mint)	256
		NRT: Nicotine Gum 4mg (Fruit)	192
		NRT: Nicotine Gum 4mg (Mint)	256
		NRT: Nicotine Lozenges 1mg	540
		NRT: Nicotine Lozenges 2mg	432
		NRT: Nicotine Patches 21mg	1800
		NRT: Nicotine Patches 14mg	600
Te Awamutu	21	NRT: Nicotine Patches 21mg	600
Trentham	22	NRT: Nicotine Patches 21mg	120
Whakatane	23	NRT: Nicotine Gum 2mg (Fruit)	128
		NRT: Nicotine Gum 2mg (Mint)	128
		NRT: Nicotine Gum 4mg (Fruit)	128
		NRT: Nicotine Gum 4mg (Mint)	128
		NRT: Nicotine Lozenges 1mg	108
		NRT: Nicotine Lozenges 2mg	108
		NRT: Nicotine Patches 21mg	120
		NRT: Nicotine Patches 14mg	120
Whanganui	24	NRT: Nicotine Patches 21mg	120
	25	NRT: Nicotine Gum 2mg (Fruit)	80
		NRT: Nicotine Gum 2mg (Mint)	48
		NRT: Nicotine Lozenges 1mg	108
		NRT: Nicotine Lozenges 2mg	216
		NRT: Nicotine Patches 21mg	420
		NRT: Nicotine Patches 14mg	120
		NRT: Nicotine Patches 7mg	60
	26	NRT: Nicotine Lozenges 1mg	108
		NRT: Nicotine Lozenges 2mg	108
Whangarei	27	NRT: Nicotine Gum 2mg (Fruit)	55
		NRT: Nicotine Gum 2mg (Mint)	78
		NRT: Nicotine Gum 4mg (Fruit)	48
		NRT: Nicotine Gum 4mg (Mint)	60
		NRT: Nicotine Lozenges 1mg	82
		NRT: Nicotine Patches 21mg	195
		NRT: Nicotine Patches 14mg	184
		NRT: Nicotine Patches 7mg	124
	28	NRT: Nicotine Gum 2mg (Fruit)	60
		NRT: Nicotine Gum 2mg (Mint)	14
		NRT: Nicotine Gum 4mg (Fruit)	55
		NRT: Nicotine Gum 4mg (Mint)	12
		NRT: Nicotine Lozenges 1mg	114
		NRT: Nicotine Lozenges 2mg	196
		NRT: Nicotine Patches 21mg	195
		NRT: Nicotine Patches 14mg	80
		NRT: Nicotine Patches 7mg	10

Location	Order Number	Description	Number of Packs
Auckland	1	NRT: Nicotine Lozenges 1mg	54
		NRT: Nicotine Lozenges 2mg	54
	2	NRT: Nicotine Patches 21mg	600
	3	NRT: Nicotine Lozenges 1mg	54
		NRT: Nicotine Lozenges 2mg	324
	4	NRT: Nicotine Gum 2mg (Fruit)	32
		NRT: Nicotine Gum 4mg (Fruit)	96
		NRT: Nicotine Gum 4mg (Mint)	240
		NRT: Nicotine Lozenges 1mg	486
		NRT: Nicotine Lozenges 2mg	864
		NRT: Nicotine Patches 21mg	1440
		NRT: Nicotine Patches 14mg	1260
		NRT: Nicotine Patches 7mg	540
Blenheim	5	NRT: Nicotine Gum 2mg (Fruit)	31
		NRT: Nicotine Gum 2mg (Mint)	16
		NRT: Nicotine Gum 4mg (Fruit)	21
		NRT: Nicotine Gum 4mg (Mint)	16
		NRT: Nicotine Lozenges 1mg	30
		NRT: Nicotine Lozenges 2mg	30
		NRT: Nicotine Patches 21mg	85
		NRT: Nicotine Patches 14mg	20
		NRT: Nicotine Patches 7mg	5
Christchurch	6	NRT: Nicotine Lozenges 1mg	162
	-	NRT: Nicotine Lozenges 2mg	216
		NRT: Nicotine Patches 21mg	180
		NRT: Nicotine Patches 14mg	60
	7	NRT: Nicotine Lozenges 1mg	80
		NRT: Nicotine Lozenges 2mg	80
		NRT: Nicotine Patches 21mg	10
		NRT: Nicotine Patches 14mg	10
	8	NRT: Nicotine Gum 2mg (Fruit)	216
	U U	NRT: Nicotine Gum 2mg (Mint)	210
		NRT: Nicotine Gum 4mg (Fruit)	132
		NRT: Nicotine Gum 4mg (Pruit)	132
		NRT: Nicotine Lozenges 1mg	324
		NRT: Nicotine Lozenges 2mg	324
		NRT: Nicotine Patches 21mg	360
		NRT: Nicotine Patches 14mg	300
		C C	
Gisborne	9	NRT: Nicotine Patches 7mg	240
	3	NRT: Nicotine Gum 2mg (Fruit)	32
Orecurrent		NRT: Nicotine Gum 2mg (Mint)	84
		NRT: Nicotine Gum 4mg (Fruit)	32
		NRT: Nicotine Gum 4mg (Mint)	84
		NRT: Nicotine Lozenges 1mg	216
		NRT: Nicotine Lozenges 2mg	236
		NRT: Nicotine Patches 21mg	260
		NRT: Nicotine Patches 14mg	260
	40	NRT: Nicotine Patches 7mg	240
Greymouth	10	NRT: Nicotine Gum 2mg (Fruit)	96

Table 2. Summary of October 2016 NRT Orders – 34 sites

I	I	NPT: Nicotino Gum 4mg (Fruit)	96
		NRT: Nicotine Gum 4mg (Fruit) NRT: Nicotine Gum 4mg (Mint)	64
		NRT: Nicotine Lozenges 1mg	216
		NRT: Nicotine Lozenges 2mg	216
		NRT: Nicotine Patches 21mg	300
		NRT: Nicotine Patches 14mg	300
		NRT: Nicotine Patches 7mg	300
Hamilton	11	NRT: Nicotine Gum 2mg (Fruit)	128
		NRT: Nicotine Gum 2mg (Mint)	128
		NRT: Nicotine Gum 4mg (Fruit)	128
		NRT: Nicotine Gum 4mg (Mint)	128
		NRT: Nicotine Lozenges 1mg	216
		NRT: Nicotine Lozenges 2mg	210
		NRT: Nicotine Patches 21mg	600
		NRT: Nicotine Patches 14mg	600
		NRT: Nicotine Patches 7mg	240
	12	NRT: Nicotine Gum 2mg (Fruit)	112
	12	NRT: Nicotine Gum 2mg (Huit)	240
		NRT: Nicotine Gum 2mg (Mint)	240
		NRT: Nicotine Gum 4mg (Mint)	192
		NRT: Nicotine Lozenges 1mg	270
		NRT: Nicotine Lozenges 2mg	756
		NRT: Nicotine Patches 21mg	900
		NRT: Nicotine Patches 14mg	360
		5	360
Hastings	13	NRT: Nicotine Patches 7mg	40
Tustings	10	NRT: Nicotine Gum 2mg (Fruit) NRT: Nicotine Gum 2mg (Mint)	40
		NRT: Nicotine Gum 2mg (Mint)	60
		NRT: Nicotine Gum 4mg (Mint)	60
		NRT: Nicotine Lozenges 1mg	60
		NRT: Nicotine Lozenges 2mg	60
		NRT: Nicotine Patches 21mg	160
		NRT: Nicotine Patches 14mg	80
	14	NRT: Nicotine Gum 2mg (Fruit)	54
		NRT: Nicotine Gum 2mg (Mint)	50
		NRT: Nicotine Gum 4mg (Fruit)	4
		NRT: Nicotine Lozenges 1mg	42
		NRT: Nicotine Lozenges 2mg	72
		NRT: Nicotine Patches 21mg	240
		NRT: Nicotine Patches 14mg	75
		NRT: Nicotine Patches 7mg	15
	15	NRT: Nicotine Gum 2mg (Fruit)	50
		NRT: Nicotine Gum 2mg (Mint)	30
		NRT: Nicotine Gum 4mg (Fruit)	30
		NRT: Nicotine Lozenges 1mg	30
		NRT: Nicotine Lozenges 2mg	40
		NRT: Nicotine Patches 21mg	80
		NRT: Nicotine Patches 2 mg	60
Invercargill	16	NRT: Nicotine Gum 2mg (Fruit)	48
		NRT: Nicotine Gum 2mg (Mint)	48
		NRT: Nicotine Gum 2mg (Mint) NRT: Nicotine Gum 4mg (Fruit)	40
		,	
		NRT: Nicotine Gum 4mg (Mint)	48

l.		NRT: Nicotine Lozenges 1mg	324
		NRT: Nicotine Lozenges 2mg	162
		NRT: Nicotine Patches 21mg	180
		NRT: Nicotine Patches 7mg	180
Kaitaia	17	NRT: Nicotine Lozenges 1mg	162
		NRT: Nicotine Lozenges 2mg	324
Lower Hutt	18	NRT: Nicotine Gum 2mg (Fruit)	5
		NRT: Nicotine Gum 4mg (Fruit)	21
		NRT: Nicotine Gum 4mg (Mint)	128
		NRT: Nicotine Lozenges 1mg	10
		NRT: Nicotine Lozenges 2mg	226
		NRT: Nicotine Patches 21mg	420
		NRT: Nicotine Patches 2 mg	420 60
Manukau City	19		48
	19	NRT: Nicotine Gum 2mg (Fruit)	40 96
		NRT: Nicotine Gum 4mg (Fruit)	
		NRT: Nicotine Gum 4mg (Mint)	16
		NRT: Nicotine Lozenges 1mg	54
		NRT: Nicotine Lozenges 2mg	324
		NRT: Nicotine Patches 21mg	420
Milburn	20	NRT: Nicotine Patches 14mg	60
MIDUITI	20	NRT: Nicotine Lozenges 2mg	162
Palmerston North	21	NRT: Nicotine Patches 21mg	60
Paimerston North	21	NRT: Nicotine Lozenges 1mg	324
	22	NRT: Nicotine Lozenges 2mg	324
	22	NRT: Nicotine Gum 2mg (Mint)	20
		NRT: Nicotine Gum 4mg (Fruit)	64
		NRT: Nicotine Lozenges 1mg	20
		NRT: Nicotine Lozenges 2mg	108
		NRT: Nicotine Patches 21mg	180
		NRT: Nicotine Patches 14mg	20
		NRT: Nicotine Patches 7mg	20
	23	NRT: Nicotine Gum 2mg (Fruit)	112
		NRT: Nicotine Gum 2mg (Mint)	112
		NRT: Nicotine Gum 4mg (Fruit)	112
		NRT: Nicotine Gum 4mg (Mint)	112
		NRT: Nicotine Lozenges 1mg	378
		NRT: Nicotine Lozenges 2mg	756
		NRT: Nicotine Patches 21mg	840
		NRT: Nicotine Patches 14mg	420
_	-	NRT: Nicotine Patches 7mg	420
Rotorua	24	NRT: Nicotine Gum 2mg (Fruit)	80
		NRT: Nicotine Gum 2mg (Mint)	80
		NRT: Nicotine Lozenges 1mg	270
		NRT: Nicotine Lozenges 2mg	270
		NRT: Nicotine Patches 21mg	630
	25	NRT: Nicotine Gum 2mg (Fruit)	200
		NRT: Nicotine Gum 2mg (Mint)	200
		NRT: Nicotine Gum 4mg (Fruit)	200
		NRT: Nicotine Gum 4mg (Mint)	200
		NRT: Nicotine Lozenges 1mg	300
		NRT: Nicotine Lozenges 2mg	300
		NRT: Nicotine Patches 21mg	300

		NRT: Nicotine Patches 14mg	300
		NRT: Nicotine Patches 7mg	300
Te Awamutu	26	NRT: Nicotine Patches 21mg	600
Timaru	27	NRT: Nicotine Gum 2mg (Fruit)	24
		NRT: Nicotine Gum 2mg (Mint)	24
		NRT: Nicotine Gum 4mg (Fruit)	48
		NRT: Nicotine Gum 4mg (Mint)	48
		NRT: Nicotine Lozenges 1mg	74
		NRT: Nicotine Lozenges 2mg	192
		NRT: Nicotine Patches 21mg	210
		NRT: Nicotine Patches 14mg	140
		NRT: Nicotine Patches 7mg	70
Trentham	28	NRT: Nicotine Lozenges 1mg	270
		NRT: Nicotine Lozenges 2mg	540
Wellington	29	NRT: Nicotine Lozenges 1mg	108
		NRT: Nicotine Lozenges 2mg	216
Westown	30	NRT: Nicotine Gum 2mg (Fruit)	32
		NRT: Nicotine Lozenges 2mg	162
		NRT: Nicotine Patches 21mg	180
Whakatane	31	NRT: Nicotine Lozenges 1mg	162
		NRT: Nicotine Lozenges 2mg	162
		NRT: Nicotine Patches 21mg	240
		NRT: Nicotine Patches 14mg	240
		NRT: Nicotine Patches 7mg	60
Whanganui	32	NRT: Nicotine Lozenges 2mg	20
		NRT: Nicotine Patches 14mg	300
	33	NRT: Nicotine Gum 2mg (Fruit)	96
		NRT: Nicotine Gum 2mg (Mint)	64
		NRT: Nicotine Gum 4mg (Fruit)	48
		NRT: Nicotine Gum 4mg (Mint)	80
		NRT: Nicotine Lozenges 1mg	270
		NRT: Nicotine Lozenges 2mg	324
		NRT: Nicotine Patches 21mg	300
		NRT: Nicotine Patches 14mg	180
		NRT: Nicotine Patches 7mg	180
Whangarei	34	NRT: Nicotine Gum 2mg (Fruit)	123
		NRT: Nicotine Gum 2mg (Mint)	98
		NRT: Nicotine Gum 4mg (Fruit)	207
		NRT: Nicotine Gum 4mg (Mint)	108
		NRT: Nicotine Lozenges 1mg	205
		NRT: Nicotine Lozenges 2mg	281
		NRT: Nicotine Patches 21mg	603
		NRT: Nicotine Patches 14mg	287
		NRT: Nicotine Patches 7mg	171